GDTC · CytoMed Therapeutics Ltd
United States · RS rating 28 · As of 2026-10-14
| Price | 0.86 USD |
|---|---|
| 1-day change | -1.2% |
| RS rating (overall / 1M / 3M / 12M) | 28 / 91 / 24 / 12 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 20 / 18 / 9 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +68.0% |
| Market cap (USD) | $12.0M |